Clinical Trial Detail

NCT ID NCT02642965
Title Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Children's Oncology Group
Indications

acute myeloid leukemia

Therapies

CPX-351 + Cytarabine + Filgrastim + Fludarabine

Age Groups: adult child

No variant requirements are available.